Clin Endosc.  2019 Sep;52(5):502-505. 10.5946/ce.2018.176.

Endoscopic Submucosal Dissection Followed by Concurrent Chemoradiotherapy in Patients with Early Esophageal Cancer with a High Risk of Lymph Node Metastasis

• Kim HK
• Ko WJ
• Kwon CI
• Song GW
• Yoo IK
• Song JH
• Kim HS
• Cho JY

• KMID: 2464673
• DOI: http://doi.org/10.5946/ce.2018.176

Abstract

Endoscopic submucosal dissection is recommended as an alternative therapy for early esophageal cancer. However, achieving curative resection in this procedure remains controversial since precise prediction of lymph node metastasis can be difficult. Here, we present the preliminary results of endoscopic submucosal dissection followed by concurrent chemoradiotherapy for early esophageal cancer with a high risk of lymph node metastasis. From May 2006 to January 2014, six patients underwent concurrent chemoradiotherapy after endoscopic submucosal dissection with a median follow-up period of 63 months. No complications were encountered during concurrent chemoradiotherapy. Although local recurrence did not occur in all patients, two patients were diagnosed with metachronous cancer. Overall, the survival rate was 100%. Thus, endoscopic submucosal dissection followed by concurrent chemoradiotherapy may be a feasible treatment for early esophageal cancer in patients with a high risk of lymph node metastasis. Future prospective large-scale studies are warranted to confirm our results.

Keyword

Early esophageal cancer; Concurrent chemoradiotherapy; Endoscopic submucosal dissection

MeSH Terms

Chemoradiotherapy*
Esophageal Neoplasms*
Follow-Up Studies
Humans
Lymph Nodes*
Neoplasm Metastasis*
Prospective Studies
Recurrence
Survival Rate